


Supplemental Figure S1. Exploratory analysis of *PI3K* and *BCR* gene expression profiles and clinical outcomes in 8 patients with available gene expression data.

Best response	Outcome data				Tumor RNA expression (WGS)				
	PFS, months	Censored PFS	TTD, days	Censored TTD	React PI3K	PI3K	Biocarta-BCR	KEGG-BCR	BCR
CR	23.2	1	727	1	44.1	29.1	47.4	61.7	32.1
PR	18.4	0	880	1	43.8	29.3	47.6	62.7	33.2
PR	10.6	1	509	0	43.3	28.7	44.2	56.4	28.2
PR	4.8	1	1306	1	42.4	27.6	42.1	55.0	27.4
PR	5.0	1	863	1	41.3	25.5	38.0	49.2	25.8
PR	19.5	1	854	1	40.8	26.5	40.3	51.6	26.9
SD	6.2	1	245	1	39.0	23.6	35.7	47.3	22.7
NE	1.0	0	1022	1	40.6	26.4	38.6	50.5	26.2



BCR, B-cell antigen receptor; CR, complete response; KEGG, Kyoto Encyclopedia of Genes and Genomes;¹ NE, not evaluable; PFS, progression-free survival; PI3K, pan-class I phosphoinositide 3-kinase; PR, partial response; SD, stable disease; TTD, time to treatment discontinuation; WGS, weighted gene expression score.

Reference

1. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. *Nucleic Acids Res.* 2004;32(1):D277-D280.